Clinical trials: Obsessive Compulsive Disorders
Depression, Anxiety
Focused Ultrasound for Behavioral Health
This is a double-blind, within-participant crossover, multi-site dose-finding study evaluating the safety, feasibility, and preliminary efficacy of repeated low-intensity focused ultrasound (LIFU) stimulation using the ATTN201…
- Conditions
- Depression, Anxiety, Obsessive Compulsive Disorder (OCD)
- Trial name
- VANTUS (NCT07851038)
- Testing
- ATTN201 head-worn focused ultrasound
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Attune Neurosciences Inc
Obsessive-Compulsive Disorder
A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder
The purpose of this study was to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in participants with Obsessive Compulsive Disorder (OCD).
- Trial name
- NCT04693351
- Testing
- Troriluzole
- Where
- 89 sites in United States, Canada and 5 more
- Volunteers
- 589 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Obsessive Compulsive Disorder
Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compulsive disorder (OCD).
- Trial name
- NCT04708834
- Testing
- Troriluzole (BHV-4157)
- Where
- 175 sites in United States, Canada and 4 more
- Volunteers
- 772 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Obsessive-Compulsive Disorder
Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder
The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive disorder (OCD) who had an inadequate response to selective serotonin reuptake…
- Trial name
- NCT03299166
- Testing
- Troriluzole
- Where
- 57 sites in United States
- Volunteers
- 426 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Obsessive-Compulsive Disorder
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
- Trial name
- NCT04641143
- Testing
- Troriluzole
- Where
- 73 sites in United States
- Volunteers
- 456 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Autism Spectrum Disorder, Depression - Major Depressive Disorder
Mental Health, Intellectual and Neurodevelopmental Disorder Detection With Artificial Intelligence Models
This study investigates whether AI-driven analysis of speech can accurately predict clinical diagnoses and assess risk for various mental or behavioral health conditions, including attention-deficit/hyperactivity disorder (ADHD)…
- Conditions
- Autism Spectrum Disorder, Depression - Major Depressive Disorder, Anxiety, Generalized, Bipolar Disorder (BD)
- Trial name
- MINDAIM (NCT06792175)
- Testing
- Solicue Machine Learning Models, Mercuria Machine Learning Models
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- Psyrin Inc.
Obsessive Compulsive Disorder (OCD), Bipolar Disorders
Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions
This is a research study looking at whether the way people speak can help predict how well they'll respond to certain mental health treatments.
- Conditions
- Obsessive Compulsive Disorder (OCD), Bipolar Disorders, Major Depressive Disorder, Post-Traumatic Stress Disorder, PTSD
- Trial name
- NCT06823024
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Psyrin Inc.
Anxiety, Obsessive-Compulsive Disorder
Virtual Reality System for Anxiety and OCD
Cognitive Behavioral Therapy with fear provoking exposures is the most effective therapy for anxiety disorders. The investigators aim to enhance this therapy with the use of virtual reality exposures.
- Trial name
- NCT03636022
- Testing
- VR System, Control
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Minnesota HealthSolutions
Obsessive-Compulsive Disorder
Child and Adolescent OCD Outcomes From Exposure and Response Prevention Video Teletherapy Treatment
This is a naturalistic, observational study of children and adolescents with obsessive-compulsive disorder who were treated with exposure and response prevention via video teletherapy.
- Trial name
- NCT06466447
- Testing
- Exposure and response prevention therapy
- Where
- United States
- Volunteers
- 2,173 people
- Sponsor
- NOCD
Post-traumatic Stress Disorder (PTSD)
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
- Trial name
- NCT05189977
- Testing
- Propranolol, Prazosin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Posttraumatic Stress Disorder (PTSD), Avoidant Personality Disorder
Effectiveness of PTSD-treatment Compared to Integrated PTSD-PD-treatment in Adult Patients With Comorbid PTSD and CPD
The goal of PROSPER-C is to study effectiveness of ImRs compared to integrated SFT-ImRs in treatment-seeking, adult patients with comorbid PTSD and Cluster C Personality Disorder (CPD).
- Conditions
- Posttraumatic Stress Disorder (PTSD), Avoidant Personality Disorder, Dependent Personality Disorder, Obsessive Compulsive Personality Disorder
- Trial name
- PROSPER-C (NCT03833531)
- Testing
- ImRS, SFT
- Where
- Netherlands
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Arkin
OCD, Obsessive-Compulsive Disorder
Discovering Factors in the Clinical Study Journey of Patients With OCD
This research aims to collect comprehensive data on the clinical trial experience of OCD patients. Its goal is to identify the factors that limit patients' ability to join or complete a trial successfully.
- Trial name
- NCT05881356
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Obsessive-compulsive Disorders and Symptoms, Obsessive-Compulsive Disorder
An ERP-based Mobile Intervention as an Adjunctive Treatment for OCD
The objective of this feasibility study is to evaluate the feasibility, acceptability, and potential usefulness of the investigational device, a mobile software application (app) (OC Free) for treatment of OCD (contamination…
- Trial name
- NCT05166707
- Testing
- BIXINK OC Free
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- BIXINK Therapeutics Co., Ltd.
Obsessive-Compulsive Disorder
Evaluation of the Long Term Efficacy and Durability of the BrainsWay Deep TMS in OCD Subjects
A Prospective Double Blind Randomized Controlled Trial to Evaluate the Long Term Efficacy and Durability of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) in Obsessive-Compulsive Subjects
- Trial name
- NCT05404360
- Testing
- BrainsWay Deep TMS HAC/H7-Coil
- Volunteers
- 124 people
- Sponsor
- Brainsway
Obsessive Compulsive Disorder
Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)
To evaluate the long-term impact of treatment with sertraline on aspects of cognitive, emotional and physical development and pubertal maturation in pediatric subjects ages 6 to 16 years (inclusive) with a diagnosis of anxiety…
- Trial name
- SPRITES (NCT01302080)
- Testing
- sertraline, psychotherapy
- Where
- 44 sites in United States
- Volunteers
- 941 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Obsessive-Compulsive Disorder
Clinical Outcomes From NOCD Treatment of Obsessive-Compulsive Disorder Using Exposure and Response Prevention
This is a naturalistic, observational study of individuals with obsessive-compulsive disorder who were treated with exposure and response prevention via video teletherapy, augmented with between-session support with text…
- Trial name
- NCT04701372
- Testing
- Exposure and response prevention therapy
- Where
- United States
- Volunteers
- 2,069 people
- Sponsor
- NOCD
Obsessive Compulsive Disorder
An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD
The purpose of the study is to evaluate the safety and efficacy of the Deep TMS (DTMS) treatment in subjects with OCD. The device technology is based on the application of deep brain TMS by means of repetitive pulse trains at a…
- Trial name
- NCT02229903
- Testing
- Active DTMS Treatment
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 100 people
- Sponsor
- Brainsway
Obsessive Compulsive Disorder
Tolerability, Safety and Efficacy of the HAC-Coil Deep Transcranial Magnetic Stimulation in Medication Resistance Obsessive Compulsive Disorder (OCD) Subjects
The purpose of this study is to test whether the combination of deep transcranial magnetic stimulation (DTMS) treatment with customary medication for obsessive compulsive disorder (OCD) patients is effective than treatment that…
- Trial name
- NCT01343732
- Testing
- Deep TMS
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Brainsway
Medication-refractory Obsessive Compulsive Disorder (OCD)
ExAblate Treatment of Medication Refractory Obsessive Compulsive Disorder
The goal of this prospective, non-randomized, single-arm, single site, feasibility study is to develop and collect data to evaluate the safety and initial effectiveness of this treatment using this ExAblate transcranial System in…
- Trial name
- NCT01986296
- Testing
- ExAblate Transcranial MRgFUS System
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- InSightec
Pediatric Acute-Onset Neuropsychiatric Syndrome, Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections
A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
This study will evaluate the use of intravenous immunoglobulins (IVIG) at a dose of 1g/Kg/body weight given every three weeks for 6 infusions in pediatric subjects ages 4 - 16 years with moderate to severe PANS.
- Trial name
- PANS (NCT03348618)
- Testing
- IVIG
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- IMMUNOe Research Centers